Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use

Lignende værker

• Nivolumab treatment beyond RECIST‐defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial
  af: Haddad, Robert, et al.
  Udgivet: (2019)
• CheckMate 141: 1‐Year Update and Subgroup Analysis of Nivolumab as First‐Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer
  af: Gillison, Maura L., et al.
  Udgivet: (2018)
• Nivolumab versus investigator’s choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age
  af: Saba, Nabil F., et al.
  Udgivet: (2019)
• Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
  af: Ferris, Robert L., et al.
  Udgivet: (2018)
• Impact of nivolumab vs standard, single-agent therapy of investigator’s choice on patient-reported outcomes in recurrent or metastatic squamous cell carcinoma of the head and neck: health-related quality-of-life results from CheckMate 141, a randomized, phase 3 trial
  af: Harrington, Kevin J, et al.
  Udgivet: (2017)